← back

Untitled

A lot of teams still talk about interoperability as if it were a civic virtue. It is a workflow problem with regulatory teeth. CMS has kept updating its standards pages and implementation guides, and the 2026 proposed rule for prior authorization for drugs would require specific standards for SCRIPT, Formulary and Benefit, RTPB, and CDex, with the policy clock pointed toward October 1, 2027 for several of those changes. That gives vendors time on paper and very little mercy in practice.

Picture the operator at 6:40 p.m. in a trial operations office, staring at a failed exchange because the patient record in one system says the chart note is final while the payer side still treats the attachment as provisional. The message is cleanly formatted, the transaction is technically valid, and the evidence still stalls. Somewhere between the EHR, the payer API, and the sponsor system, ownership of the handoff got vague, which is where compliance work tends to start sweating.

CMS is making the interface more concrete by naming APIs and standards instead of asking the market to improvise. Its interoperability pages now point directly to FHIR based APIs, US Core, SMART on FHIR, OpenID Connect, and related implementation guides, while the proposed drug prior authorization rule adds payer side standards and attachment rules into the same operational picture. That is useful because it narrows the room for ornamental compliance. It also exposes the weak seam between policy language and the software contract that a vendor signs, tests, version controls, and then has to defend when the payload does not match the expectation.

Pharma feels that seam in clinical operations, medical affairs, and the grim little spaces where regulated data is handed from one system to another. A study document, adverse event report, or prior auth support packet is only as trustworthy as the chain that moves it. If the API hands off a resource but the receiving system cannot preserve the version, the provenance, or the audit event, the evidence chain becomes a story told after the fact. Good luck explaining that to quality when the exception queue is already full.

The uncomfortable part is that disagreement between systems is usually treated as a software nuisance when it is often a governance failure with a technical receipt. Who owns the correction when the payer rejects a CDex attachment, the sponsor has already locked the trial file, and the vendor swears the interface passed validation? The answer should live in the contract, the test plan, and the operating procedure together. If it lives in only one of those places, somebody in the audit will end up carrying the mismatch alone.

This is where the current CMS activity matters beyond health plan admin. The more explicitly CMS defines the exchange surface, the less room there is for vague vendor promises and the more visible the real work becomes: schema mapping, version control, access logging, exception handling, replayability, and proof that the data that left one system is the data that arrived in the other. Priya Nair would probably call that the honest part of the job. It is the part where people admit that validation did not remove pain; it only documented who will answer for it.

The next fight is going to happen at the interface between regulation, software contracts, and the workflow that carries patient or trial data. That is where interoperability becomes real, and where the audit either survives or quietly fragments.' tags: - technology-trends - apis - pharma title: The Audit Trail Moves Where the API Stops type: technology_trends

Related

The Trial Data Problem Is Meaning, Not GlassCell therapy scale meets the factory floorWhen the Physics of Peptide Hit the Audit Wall